- Home
- RFI vs ABSI Comparison
RFI vs ABSI Comparison
Compare RFI & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFI | ABSI |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.2M | 577.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RFI | ABSI |
|---|---|---|
| Price | $10.88 | $3.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.98 |
| AVG Volume (30 Days) | 69.8K | ★ 4.1M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,815,000.00 |
| Revenue This Year | N/A | $10.72 |
| Revenue Next Year | N/A | $437.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.62 | $2.01 |
| 52 Week High | $12.52 | $6.33 |
Technical Indicators
Market Signals| Indicator | RFI | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 56.83 |
| Support Level | $10.90 | $3.37 |
| Resistance Level | $11.02 | $3.64 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 16.98 | 69.80 |
Price Performance
Historical ComparisonAbout RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.